La información sobre Enfermedad Inflamatoria Intestinal (Crohn y Colitis Ulcerosa) que in-pacient.es pone a tu disposición está basada en las fuentes bibliográficas que se citan a continuación, así como en la propia experiencia del Comité Editorial y revisores de in-pacient.es  Además ésta se revisa de forma periódica por dicho Comité  Editorial, con el fin de mantenerla actualizada.

Los enlaces dirigidos a páginas web pueden no estar disponibles por causas ajenas a nuestra voluntad, por lo que pedimos disculpas y agradeceremos que nos informes de estas anomalías para poder subsanarlas a través del siguiente formulario

Referencias:

Baumgart DC et al.
Crohn’s disease.
Lancet. 2012 Nov 3;380(9853):1590-605

Benchimol EI et al.
Traditional corticosteroids for induction of remission in Crohn’s disease.
Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006792.

Bernstein CN et al.
World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010.
Inflamm Bowel Dis. 2010 Jan;16(1):112-24

Bewtra M et al.
Crohn’s disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis.
Inflamm Bowel Dis. 2013 Mar;19(3):599-613

Biancone L et al.
European evidence-based Consensus on the management of ulcerative colitis: Special situations.
J Crohns Colitis. 2008 Mar;2(1):63-92

Binion DG et al.
Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn’s disease: a meta-analysis.
Can J Gastroenterol. 2011 Sep;25(9):492-6

Burger D et al.
Conventional medical management of inflammatory bowel disease.
Gastroenterology. 2011 May;140(6):1827-1837.e2.

Cabriada JL et al.
[Recommendations of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease].
Gastroenterol Hepatol. 2013 Mar;36(3):127-46.

Castillo MD et al.
Cuestionarios de medida e impacto de la fatiga en la percepción de salud en la enfermedad inflamatoria intestinal
Rev Esp Enferm Dig. 2013;105(3):144-153

Compston J.
Osteoporosis in inflammatory bowel disease.
Gut. 2003 Jan;52(1):63-4

Cosnes J et al.
Epidemiology and natural history of inflammatory bowel diseases.
Gastroenterology. 2011 May;140(6):1785-94

Dias CC et al.
Clinical prognostic factors for disabling Crohn’s disease: a systematic review and meta-analysis.
World J Gastroenterol. 2013 Jun 28;19(24):3866-71.

Dionisio PM et al.
Capsule endoscopy has a significantly higher diagnostic yield in patients with suspected and established small-bowel Crohn’s disease: a meta-analysis.
Am J Gastroenterol. 2010 Jun;105(6):1240-8

Do VT et al.
Probiotics for maintaining remission of ulcerative colitis in adults.
Ann Pharmacother. 2010 Mar;44(3):565-71

Ephgrave K
Extra-intestinal manifestations of Crohn’s disease.
Surg Clin North Am. 2007 Jun;87(3):673-80

Feagins LA et al.
Do non-steroidal anti-inflammatory drugs cause exacerbations of inflammatory bowel disease?
Dig Dis Sci. 2010 Feb;55(2):226-32

Feller M et al.
Long-term antibiotic treatment for Crohn’s disease: systematic review and meta-analysis of placebo-controlled trials.
Clin Infect Dis. 2010 Feb 15;50(4):473-80.

Ford AC et al.
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.
Am J Gastroenterol. 2011 Apr;106(4):644-59

Gisbert JP et al.
Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis
Aliment Pharmacol Ther. 2009 Jul 1;30(2):126-37

Gomollón F et al.
Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU.
Gastroenterol Hepatol. 2013 Feb;36(2):104-14

Hart AR et al.
Diet in the aetiology of ulcerative colitis: a European prospective cohort study.
Digestion. 2008;77(1):57-64

Higgins PD et al.
Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares.
Aliment Pharmacol Ther. 2009 Feb 1;29(3):247-57.

Hoentjen F et al.
Second-generation corticosteroids for the treatment of Crohn’s disease and ulcerative colitis: more effective and less side effects?
Dig Dis. 2012;30(4):368-75.

Hoentjen F et al.
Update on the management of ulcerative colitis.
Curr Gastroenterol Rep. 2011 Oct;13(5):475-85

Iglesias M et al.
Psychological impact of Crohn’s disease on patients in remission: anxiety and depression risks.
Rev Esp Enferm Dig. 2009 Apr;101(4):249-57.

Jackson CA et al.
Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review.
Am J Gastroenterol. 2010 Mar;105(3):525-39

Jess T et al.
Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies
Clin Gastroenterol Hepatol. 2012 Jun;10(6):639-45

Jones DT et al.
Passive smoking and inflammatory bowel disease: a meta-analysis.
Am J Gastroenterol. 2008 Sep;103(9):2382

Joos S.
Review on efficacy and health services research studies of complementary and alternative medicine in inflammatory bowel disease.
Chin J Integr Med. 2011 Jun;17(6):403-9.

Kornbluth A et al.
Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee
Am J Gastroenterol. 2010 Mar;105(3):501-23

Laukoetter MG et al.
Intestinal cancer risk in Crohn’s disease: a meta-analysis.
J Gastrointest Surg. 2011 Apr;15(4):576-8

Lee TW et al.
Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis.
J Crohns Colitis. 2012 Apr;6(3):267-75

Lichtenstein GR et al.
Management of Crohn’s disease in adults.
Am J Gastroenterol. 2009 Feb;104(2):465-83

López MA et al.
Adaptation into Spanish of the Warwick-Edinburgh Mental Well-being Scale (WEMWBS) and preliminary validation in a student sample.
Qual Life Res. 2013 Jun;22(5):1099-104.

López-Serrano P et al.
Epidemiologic study on the current incidence of inflammatory bowel disease in Madrid.
Rev Esp Enferm Dig. 2009 Nov;101(11):768-72.

Mawdsley JE et al.
Psychological stress in IBD: new insights into pathogenic and therapeutic implications.
Gut. 2005 Oct;54(10):1481-91

Mayberry JF et al.
NICE clinical guideline (CG152): the management of Crohn’s disease in adults, children and young people.
Aliment Pharmacol Ther. 2013 Jan;37(2):195-203

Meier J et al.
Current treatment of ulcerative colitis.
World J Gastroenterol. 2011 Jul 21;17(27):3204-12.

Moreira VF et al.
Enfermedad de Crohn perianal (información al paciente)
Rev Esp Enferm Dig. 2007; 99(7):420.

Naidoo K et al.
Probiotics for maintenance of remission in ulcerative colitis.
Cochrane Database Syst Rev. 2011 Dec 7;(12):CD007443

Narula N et al.
Exercise and inflammatory bowel disease
Can J Gastroenterol. 2008 May;22(5):497-504.

Ng V et al.
Exercise and Crohn’s disease: speculations on potential benefits.
Can J Gastroenterol. 2006 Oct;20(10):657-60.

Peyrin-Biroulet L et al.
Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials.
Clin Gastroenterol Hepatol. 2008 Jun;6(6):644-53.

Pithadia AB et al.
Treatment of inflammatory bowel disease (IBD).
Pharmacol Rep. 2011;63(3):629-42.

Rochelle TL et al.
The importance of illness perceptions, quality of life and psychological status in patients with ulcerative colitis and Crohn’s disease.
J Health Psychol. 2013 Jul;18(7):972-83

Sang LX et al.
Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis.
World J Gastroenterol. 2010 Apr 21;16(15):1908-15.

Sanz J et al.
Adaptación española del Inventario para la Depresión de Beck-II (BDI-II): 2. Propiedades psicométricas en población general
Clínica y Salud 2003; 14(3):249-280

Satsangi J et al.
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.
Gut. 2006 Jun;55(6):749-53

Satsangi J et al.
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.
Gut. 2006 Jun;55(6):749-53

Schoultz M et al.
Assessment of causal link between psychological factors and symptom exacerbation in inflammatory bowel disease: a protocol for systematic review of prospective cohort studies.
Syst Rev. 2013 Jan 23;2:8.

Sides C et al.
Crohn disease and the gynecologic patient.
Obstet Gynecol Surv. 2013 Jan;68(1):51-61

Soon IS et al.
The relationship between urban environment and the inflammatory bowel diseases: a systematic review and meta-analysis.
BMC Gastroenterol. 2012 May 24;12:51

Stange EF et al.
European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis.
J Crohns Colitis. 2008 Mar;2(1):1-23

Swan K et al.
Omega-3 fatty acid for the treatment and remission of Crohn’s disease
J Complement Integr Med. 2013 May 7;10

Talley NJ et al.
An evidence-based systematic review on medical therapies for inflammatory bowel disease.
Am J Gastroenterol. 2011 Apr;106 Suppl 1:S2-25

Talley NJ et al.
An evidence-based systematic review on medical therapies for inflammatory bowel disease.
Am J Gastroenterol. 2011 Apr;106 Suppl 1:S2-25

Timmer A et al.
Psychological interventions for treatment of inflammatory bowel disease.
Cochrane Database Syst Rev. 2011 Feb 16;(2):CD006913.

Troncoso LL et al.
Ophthalmic manifestations in patients with inflammatory bowel disease: A review.
World J Gastroenterol. 2017 Aug 28;23(32):5836-5848.

Truelove SC et al.
Cortisone in ulcerative colitis; final report on a therapeutic trial.
Br Med J. 1955 Oct 29;2(4947):1041-8.

Turner D et al.
Maintenance of remission in inflammatory bowel disease using omega-3 fatty acids (fish oil): a systematic review and meta-analyses.
Inflamm Bowel Dis. 2011 Jan;17(1):336-45.

Vidal A et al.
[The impact of anxiety and depression on relapse in patients with inflammatory bowel disease].
Med Clin (Barc). 2009 Mar 7;132(8):298-302

Zhang CK et al.
The influence of depression on quality of life in patients with inflammatory bowel disease.
Inflamm Bowel Dis. 2013 Jul;19(8):1732-9